Allergan

Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol

Retrieved on: 
Tuesday, April 2, 2019
Health, Articles, Clinical research, Angiology, Anti–vascular endothelial growth factor therapy, Allergan, Pharmacovigilance

"In the Phase 3 trials previously reported, abicipar demonstrated potential that could transform the way physicians manage nAMD with anti-VEGF therapy.

Key Points: 
  • "In the Phase 3 trials previously reported, abicipar demonstrated potential that could transform the way physicians manage nAMD with anti-VEGF therapy.
  • "The results of this open-label study enabled us to assess improvements to the manufacturing process for abicipar.
  • The safety profile demonstrated in MAPLE gives us confidence to proceed and scale up manufacturing," said David Nicholson, Chief Research and Development Officer, Allergan.
  • He added: "The safety data from the MAPLE trial are an important step in the further improvement of the manufacturing process of abicipar."

Appaloosa Statement Regarding Allergan Proxy Filing

Retrieved on: 
Monday, March 25, 2019
Professional services, Banking, Finance, Horses, Shareholders, Proxy, Appaloosa, Allergan, Annual general meeting, Livestock

Appaloosa LP today issued a statement in response to Allergan plcs (NYSE:AGN) (Allergan) March 22, 2019 proxy filing and intention to install an independent Chairman at the next CEO transition.

Key Points: 
  • Appaloosa LP today issued a statement in response to Allergan plcs (NYSE:AGN) (Allergan) March 22, 2019 proxy filing and intention to install an independent Chairman at the next CEO transition.
  • Funds advised by Appaloosa LP (Appaloosa) have submitted to Allergan plc (Allergan) a shareholder proposal to separate the roles of Chairman and Chief Executive Officer to be considered at Allergans 2019 annual general meeting of shareholders.
  • This communication is not a solicitation of proxies and Appaloosa is not seeking authority to vote any proxy in connection with Allergans annual general meeting.
  • Shareholders may vote for Appaloosas shareholder proposal by executing and returning the form of proxy card furnished by Allergan in accordance with the procedures set forth in Allergans proxy materials.

Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success

Retrieved on: 
Monday, March 25, 2019
Migraine, Drugs, Clinical medicine, Medicine, Fremanezumab, Botulinum toxin, Allergan, Calcitonin gene-related peptide, Topiramate, Teva Pharmaceutical Industries

Among patients treated with preventive migraine therapies, the segment share leaders remain topiramate for episodic migraine and topiramate and Allergan's Botox for chronic migraine.

Key Points: 
  • Among patients treated with preventive migraine therapies, the segment share leaders remain topiramate for episodic migraine and topiramate and Allergan's Botox for chronic migraine.
  • Teva is considered top-of-class across multiple physician and patient support metrics, including best sales/medical affairs team and exceeding physicians' expectations on sales representatives, patient support program, and field reimbursement support.
  • In fact, Ajovy was their class-leading anti-CGRP therapy, surpassing even Botox in episodic migraine, emphasizing the vital importance of a strong promotional and support infrastructure to drive competitive success in the migraine prevention market.
  • Spherix Global Insights is an independent business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets.

Global Acne Therapeutics Market Forecasts to 2024 - Allergan, Valeant Pharmaceutical International, Bayer, and Galderma are Dominating - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2019
Health, Pharmaceutical, RTT, Acneiform eruptions, Acne, Bausch Health, Galderma, Companies, Biotechnology, Life sciences, Allergan

The "Acne Therapeutics Market- Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acne Therapeutics Market- Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The acne therapeutics market is expected to register a CAGR of nearly 4.23% during the forecast period, 2019-2024.
  • The food that is high in refined carbohydrates increases insulin, which results in hormonal problems, promoting acne formation.
  • Allergan, Valeant Pharmaceutical International, Bayer, and Galderma (Nestle Skin Health) are some of the major players in the acne therapeutics market.

Fish & Richardson Principal Martina Tyreus Hufnal Named 2019 "Influencer of Law - Rising Star" by the Philadelphia Inquirer

Retrieved on: 
Monday, March 18, 2019
Companies, Biotechnology, Fish & Richardson, Life sciences, Chemours, Gilead Sciences, Allergan, Influencer marketing, The Philadelphia Inquirer, Wilmington station

WILMINGTON, Del., March 18, 2019 /PRNewswire/ -- Fish & Richardson principal Martina Tyreus Hufnal has been named a 2019 "Influencer of Law Rising Star" by the Philadelphia Inquirer for her significant legal and community accomplishments.

Key Points: 
  • WILMINGTON, Del., March 18, 2019 /PRNewswire/ -- Fish & Richardson principal Martina Tyreus Hufnal has been named a 2019 "Influencer of Law Rising Star" by the Philadelphia Inquirer for her significant legal and community accomplishments.
  • Hufnal will be honored at an event in Philadelphia on March 26, 2019.
  • Hufnal was selected for her impressive trial work on high stakes patent litigation for clients such as Microsoft, Gilead Sciences, Allergan, iCeutica, Chemours, and Johnson Matthey.
  • Fish & Richardson , a premier global intellectual property law firm, is sought-after and trusted by the world's most innovative brands and influential technology leaders.

Global Antidepressant Market Outlook, 2019-2024 with Allergan, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson, and Pfizer Dominating - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2019
Health, Pharmaceutical, Companies, Depression, Life sciences, Articles, Pfizer, AstraZeneca, Antidepressant, Lundbeck, Allergan, Major depressive disorder

The global antidepressant market is expected to register a CAGR of nearly 2.1% during the forecast period, 2019-2024.

Key Points: 
  • The global antidepressant market is expected to register a CAGR of nearly 2.1% during the forecast period, 2019-2024.
  • The major factors for the growth of the global antidepressant market include the rising cases of depression, increasing awareness about depression, and the emergence of novel biologics.
  • The increase in the number of young adults affected by some form of depression is as high as 8%.
  • Some of the key players in the market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc.

Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting

Retrieved on: 
Thursday, March 14, 2019
Health, Drugs, Bimatoprost, Prostaglandins, Allergan, Glaucoma, Food and Drug Administration, New Drug Application

Topline Phase 3 efficacy and safety results from the ongoing studies will also be presented at a congress later this year.

Key Points: 
  • Topline Phase 3 efficacy and safety results from the ongoing studies will also be presented at a congress later this year.
  • Allergan anticipates submitting a New Drug Application (NDA) to the FDA in the second half of 2019.
  • "This first presentation showing the treatment duration from the Phase 3 studies confirms that Bimatoprost SR could represent a major paradigm shift in the management of glaucoma.
  • Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine

Retrieved on: 
Monday, March 11, 2019
Migraine, Calcitonin gene-related peptide, Ubrogepant, Allergan, Calcitonin gene-related peptide receptor antagonists, Monoclonal antibodies, Clinical medicine, Medical specialties, Neurology, Triptans, Methysergide, Migraine treatment

DUBLIN, March 11, 2019 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of migraine in adults.

Key Points: 
  • DUBLIN, March 11, 2019 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ubrogepant for the acute treatment of migraine in adults.
  • "As a leader in Chronic Migraine research for more than 20 years, Allergan looks to provide options for patients who need new acute and preventative treatments for migraine.
  • Intermittent use of ubrogepant 50 mg or 100 mg for the acute treatment of migraine attacks over one year was well-tolerated.
  • Ubrogepant is a novel, highly potent, orally-administered CGRP receptor antagonist in development for the acute treatment of migraine.

Global Human Papillomavirus (HPV) Therapeutics Market Report 2019-2023 with Market Positioning of Key Vendors - Allergan, Bausch Health, GSK, Lee's Pharmaceutical, Merck Sharp & Dohme

Retrieved on: 
Friday, March 8, 2019
Cancer, Neoplasms, Medicine, Papillomavirus, Infectious causes of cancer, RTT, Vaccines, Carcinogenesis, Human papillomavirus infection, Merck & Co., Allergan, Papilloma

DUBLIN, March 8, 2019 /PRNewswire/ -- The "Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 8, 2019 /PRNewswire/ -- The "Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.
  • The global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV.
  • ALLERGAN, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, and Merck Sharp & Dohme are some of the major companies covered in this report.

Appaloosa Issues Statement Regarding Allergan’s Failed Anti-Depression Study

Retrieved on: 
Thursday, March 7, 2019
Health, Pharmaceutical, Other Health, Professional services, Finance, Antidepressants, Peptides, Horses, Nootropics, Rapastinel, Drugs, Appaloosa, Allergan, Branches of biology

Appaloosa LP today issued a statement in response to Allergan plcs (NYSE: AGN) (Allergan) March 6, 2019 announcement that its drug, Rapastinel, failed a late stage study for treatment of major depressive disorder:

Key Points: 
  • Appaloosa LP today issued a statement in response to Allergan plcs (NYSE: AGN) (Allergan) March 6, 2019 announcement that its drug, Rapastinel, failed a late stage study for treatment of major depressive disorder:
    Yesterdays announcement that Allergans marquee pipeline drug, Rapastinel, had spectacularly failed its Phase III trials should make apparent to all that the Companys Open Science business model is broken.
  • The Boards misplaced fear of "disrupting" Allergan is wearing thin as an excuse for inaction and can only perpetuate further erosion in the shareholders investment.
  • Funds advised by Appaloosa LP (Appaloosa) have submitted to Allergan plc (Allergan) a shareholder proposal to separate the roles of Chairman and Chief Executive Officer to be considered at Allergans 2019 annual general meeting of shareholders.
  • This communication is not a solicitation of proxies and Appaloosa is not seeking authority to vote any proxy in connection with Allergans annual general meeting.